Trilla E - Search Results

1

Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome.

Mir MC, Trilla E, de Torres IM, Panizo A, Zlotta AR, Van Rhijn B, Morote J. Mir MC, et al. Among authors: trilla e. BJU Int. 2011 Jul;108(2 Pt 2):E71-6. doi: 10.1111/j.1464-410X.2010.09818.x. Epub 2010 Nov 10. BJU Int. 2011. PMID: 21070573

2

[Evaluation of the exercise test with thallium for the clinical follow-up of patients undergoing percutaneous transluminal coronary angioplasty].

Peraza C, Crexells C, Trilla E, Carrió I, Augé JM, Sanz S, Masotti M, Oriol A. Peraza C, et al. Among authors: trilla e. Rev Esp Cardiol. 1985;38 Suppl 1:53-61. Rev Esp Cardiol. 1985. PMID: 2930882 Spanish. No abstract available.

3

[Stress thallium-201 in 3-vessel disease].

Berná L, Carrió I, Serra-Grima R, Estorch M, Crexells C, Trilla E. Berná L, et al. Among authors: trilla e. Rev Esp Cardiol. 1988;41 Suppl 2:20-6. Rev Esp Cardiol. 1988. PMID: 3238146 Spanish. No abstract available.

4

The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml.

Morote J, Trilla E, Esquena S, Serrallach F, Abascal JM, Muñoz A, Id M'Hammed Y, de Torres IM. Morote J, et al. Among authors: trilla e. Eur Urol. 2002 Oct;42(4):333-7. doi: 10.1016/s0302-2838(02)00318-4. Eur Urol. 2002. PMID: 12361897

5

Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.

Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Morote J, et al. Among authors: trilla e. Int J Cancer. 2004 Mar 1;108(6):877-81. doi: 10.1002/ijc.11639. Int J Cancer. 2004. PMID: 14712491

6

Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.

Morote J, Esquena S, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX, Planas J, Catalán R, Reventós J. Morote J, et al. Among authors: trilla e. Anticancer Drugs. 2005 Sep;16(8):863-6. doi: 10.1097/01.cad.0000173474.82486.74. Anticancer Drugs. 2005. PMID: 16096434

7

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Morote J, et al. Among authors: trilla e. J Urol. 2006 May;175(5):1679-83; discussion 1683. doi: 10.1016/S0022-5347(05)00999-7. J Urol. 2006. PMID: 16600728

8

Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J. Morote J, et al. Among authors: trilla e. Urol Int. 2006;77(2):135-8. doi: 10.1159/000093907. Urol Int. 2006. PMID: 16888418

9

Case report: retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma.

Esquena S, Abascal JM, Trilla E, De Torres I, Morote J. Esquena S, et al. Among authors: trilla e. Int Urol Nephrol. 2006;38(3-4):463-5. doi: 10.1007/s11255-006-6653-8. Int Urol Nephrol. 2006. PMID: 17146608

10

[Prostate cancer. New diagnostic techniques. Current status of prostate biopsy].

Trilla E, Morote J. Trilla E, et al. Arch Esp Urol. 2006 Dec;59(10):945-52. doi: 10.4321/s0004-06142006001000002. Arch Esp Urol. 2006. PMID: 17283708 Review. Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Search Page

Filters